Atlas Trials

PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

Clinical trial NCT03013491 · TERMINATED

Trial details

NCT number
NCT03013491
Sponsor
CytomX Therapeutics
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Solid TumorLymphoma
Start date
2017-01-19
Primary completion
2020-10-27
Enrollment
196

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.